Core Insights - DexCom, Inc. is under investigation for potential violations of federal securities laws following disappointing earnings results and a significant stock price drop [1][2]. Company Performance - DexCom reported second-quarter earnings for 2024 that fell short of expectations, leading to a reduction in full-year revenue guidance from $4.35 billion to a range of $4 billion to $4.05 billion [2]. - The company attributed its poor performance to challenges in restructuring its sales force, although some analysts suggested that the rising popularity of GLP-1 weight loss drugs may have also affected sales [2]. Stock Market Reaction - Following the earnings announcement, DexCom's stock price experienced a sharp decline, closing at $107.85 per share on July 25, 2024, and dropping to approximately $66.60 per share by the next trading day, marking a decrease of $41.25 per share or 38% [2]. Legal Context - Bleichmar Fonti & Auld LLP is investigating DexCom and encourages investors to seek additional information regarding potential legal options [1][3]. - The law firm operates on a contingency fee basis, meaning shareholders will not incur costs unless the case is successful [3]. Firm Background - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and has achieved significant recoveries in past cases, including over $900 million from Tesla's Board of Directors [4].

DexCom faces several challenges, but GLP-1 drugs aren't big problems for the company right now.Going into 2024, DexCom's (DXCM 5.44%) shares were up a whopping 14 times over the last 10 years. The company's continuous glucose monitoring (CGM) devices enjoyed tremendous demand from individuals with diabetes.However, last week was the worst for DexCom stock since the company's initial public offering (IPO) in April 2005. Shares of the medical device maker plunged over 40% following DexCom's second-quarter upd ...

SAN FRANCISCO, July 29, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges DexCom, Inc. (NASDAQ: DXCM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Visit: www.hbsslaw.com/investor-fraud/DXCM Contact the Firm Now: DXCM@hbsslaw.com                                            844-916-0895 DexCom, Inc. (DXCM) Investigation: On July 26, 2024, the price of DexCom shares crate ...

NEW YORK, July 29, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Why Did DexCom’s Stock Drop? DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force re ...

The market may have overreacted to a disappointing earnings report.Last week was a tough one for Dexcom (DXCM -40.66%) shareholders. The maker of continuous blood glucose monitors lowered its forward revenue outlook when it reported second-quarter results on Friday, July 26.If there's one thing markets hate, it's uncertainty. Investors responding to management's shifting expectations hammered the stock 40.6% lower in a single trading session. That beat the stock down to a price we haven't seen since early 2 ...

These profitable businesses have a lot to offer the long-term investor.Bull markets come and go, and give way to bear markets, and come back again. The stock market has a remarkable habit of steadily rising with the passage of time. For investors who stay invested through market highs and lows, and consistently put cash to work in wonderful businesses, it's possible to compound returns over time into a profitable, extensive portfolio.If you're on the hunt for companies to buy for less than $1,000 right now, ...

NEWTOWN, Pa., July 28, 2024 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Dexcom, Inc. (NASDAQ: DXCM) resulting from allegations of providing potentially misleading business information to the investing public.If you have non-public information that could assist in the Dexcom Investigation or if you are a Dexcom investor who suffered a loss and would like to learn more, you can provide your information HERE.You can also call attorneys Eri ...

These top stocks are looking increasingly attractive for a long-term investment.Not all stocks have responded to the bull market in the some way. While many businesses have followed the broader trend of steadily rising, some stocks are trading down considerably and even coming close to historical lows.When you're looking at stocks to buy, whether shares are discounted or soaring, it's important to understand why those trends are happening and what it means for your portfolio. On that note, if you're hunting ...

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) on behalf of DexCom stockholders. Our investigation concerns whether DexCom has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On July 25, 2024, after the closure of market trading, DexCom issued a press ...

Dexcom shares sank more than 40% on Friday and headed for their worst day ever after the diabetes management company reported disappointing revenue for the second quarter and offered weak guidance. The stock fell $45.38 to $62.47 as of early afternoon, wiping out about $18 billion in market cap. Prior to Friday, the biggest drop came in September 2017, when the shares plunged 33% in a day. Dexcom held its stock market debut in 2005.Dexcom's revenue increased 15% to $1 billion from $871.3 million a year earl ...